Tailoring Therapy for Locally Advanced Breast Cancer Using Molecular Profiles: Are We There Yet?
The term ‘locally advanced breast cancer’ covers a range of clinical scenarios, and has the implications that surgical clearance and local control will be difficult or impossible, and long-term survival rates will be poor. Treatment selection is particularly important in this group of patients to tr...
Gespeichert in:
| Veröffentlicht in: | Drugs (New York, N.Y.) N.Y.), 2011-01, Vol.71 (15), p.1947-1955 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1955 |
|---|---|
| container_issue | 15 |
| container_start_page | 1947 |
| container_title | Drugs (New York, N.Y.) |
| container_volume | 71 |
| creator | Fosker, Christopher Adlard, Julian W. Shaaban, Abeer |
| description | The term ‘locally advanced breast cancer’ covers a range of clinical scenarios, and has the implications that surgical clearance and local control will be difficult or impossible, and long-term survival rates will be poor. Treatment selection is particularly important in this group of patients to try to obtain maximum control of disease, and potentially improve surgical options and cure rates.
Currently, assessment of estrogen receptor, progesterone receptor and human epidermal receptor 2 status in tumour samples remains the gold standard for prediction of response to endocrine therapy, chemotherapy or targeted agents such as trastuzumab. Progress has been made in identifying markers that can help select treatments likely to be associated with response and avoid those associated with resistance. These potential markers include Ki67 proliferation rate, cytochrome P450 (CYP) 2D6 expression, BRCA1/2 gene status and others. |
| doi_str_mv | 10.2165/11595110-000000000-00000 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_cross</sourceid><recordid>TN_cdi_gale_infotracmisc_A270375444</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A270375444</galeid><sourcerecordid>A270375444</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-f4bcbdd041a1c7836f08257d77d1a2db032ce6fb7e8a5198e591f16fec1e03863</originalsourceid><addsrcrecordid>eNqFkV1LIzEUhoO4aHX3L0hAvJxuzkw-Zi5rcVehsnvRXg-Z5ERHppOStEL_vRmmVQTB5CLnwPMeDk8IocCmOUjxG0BUAoBl7HjG6oRMAFSVQSXYKZkwBnkmpVTn5CLGl6GtRHVGznOoSgGST8jjUredD23_RJfPGPRmT50PdOGN7ro9ndlX3Ru09Dagjls6H7pAV3EIPPoOza7Tgf4P3rUdxp_kh9NdxF-H95Ks_twt5_fZ4t_fh_lskRnO5DZzvDGNtYyDBqPKQjpW5kJZpSzo3DasyA1K1ygstUiroqjAgXRoAFlRyuKSXI9zn3SHdds7vw3arNto6lmuWKEE5zxR0y-odC2uW-N7HHb-HCjHgAk-xoCu3oR2rcO-BlYP4uuj-Ppd_Fil6NUY3eyaNdr34NF0Am4OgI7JrQvJZBs_OK6YynmZuGrk4mb4FQz1i9-FPtn8fok3KWqZnQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Tailoring Therapy for Locally Advanced Breast Cancer Using Molecular Profiles: Are We There Yet?</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Fosker, Christopher ; Adlard, Julian W. ; Shaaban, Abeer</creator><creatorcontrib>Fosker, Christopher ; Adlard, Julian W. ; Shaaban, Abeer</creatorcontrib><description>The term ‘locally advanced breast cancer’ covers a range of clinical scenarios, and has the implications that surgical clearance and local control will be difficult or impossible, and long-term survival rates will be poor. Treatment selection is particularly important in this group of patients to try to obtain maximum control of disease, and potentially improve surgical options and cure rates.
Currently, assessment of estrogen receptor, progesterone receptor and human epidermal receptor 2 status in tumour samples remains the gold standard for prediction of response to endocrine therapy, chemotherapy or targeted agents such as trastuzumab. Progress has been made in identifying markers that can help select treatments likely to be associated with response and avoid those associated with resistance. These potential markers include Ki67 proliferation rate, cytochrome P450 (CYP) 2D6 expression, BRCA1/2 gene status and others.</description><identifier>ISSN: 0012-6667</identifier><identifier>EISSN: 1179-1950</identifier><identifier>DOI: 10.2165/11595110-000000000-00000</identifier><identifier>PMID: 21985164</identifier><identifier>CODEN: DRUGAY</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Antineoplastic agents ; Antineoplastic Agents, Hormonal - therapeutic use ; Biological and medical sciences ; Biomarkers, Tumor - metabolism ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - metabolism ; Cancer ; Care and treatment ; Chemotherapy ; Chemotherapy, Adjuvant ; Current Opinion ; Diagnosis ; Estrogen Receptor Modulators - therapeutic use ; Female ; Gynecology. Andrology. Obstetrics ; Health aspects ; Humans ; Internal Medicine ; Mammary gland diseases ; Medical sciences ; Medicine ; Medicine & Public Health ; Pharmacology. Drug treatments ; Pharmacology/Toxicology ; Pharmacotherapy ; Predictive Value of Tests ; Randomized Controlled Trials as Topic ; Receptor, ErbB-2 - metabolism ; Receptors, Progesterone - metabolism ; Severity of Illness Index ; Treatment Outcome ; Tumors</subject><ispartof>Drugs (New York, N.Y.), 2011-01, Vol.71 (15), p.1947-1955</ispartof><rights>Adis Data Information BV 2011</rights><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2011 Wolters Kluwer Health, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c406t-f4bcbdd041a1c7836f08257d77d1a2db032ce6fb7e8a5198e591f16fec1e03863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.2165/11595110-000000000-00000$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.2165/11595110-000000000-00000$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,778,782,27907,27908,41471,42540,51302</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24707248$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21985164$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fosker, Christopher</creatorcontrib><creatorcontrib>Adlard, Julian W.</creatorcontrib><creatorcontrib>Shaaban, Abeer</creatorcontrib><title>Tailoring Therapy for Locally Advanced Breast Cancer Using Molecular Profiles: Are We There Yet?</title><title>Drugs (New York, N.Y.)</title><addtitle>Drugs</addtitle><addtitle>Drugs</addtitle><description>The term ‘locally advanced breast cancer’ covers a range of clinical scenarios, and has the implications that surgical clearance and local control will be difficult or impossible, and long-term survival rates will be poor. Treatment selection is particularly important in this group of patients to try to obtain maximum control of disease, and potentially improve surgical options and cure rates.
Currently, assessment of estrogen receptor, progesterone receptor and human epidermal receptor 2 status in tumour samples remains the gold standard for prediction of response to endocrine therapy, chemotherapy or targeted agents such as trastuzumab. Progress has been made in identifying markers that can help select treatments likely to be associated with response and avoid those associated with resistance. These potential markers include Ki67 proliferation rate, cytochrome P450 (CYP) 2D6 expression, BRCA1/2 gene status and others.</description><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - metabolism</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Current Opinion</subject><subject>Diagnosis</subject><subject>Estrogen Receptor Modulators - therapeutic use</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Pharmacology. Drug treatments</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacotherapy</subject><subject>Predictive Value of Tests</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0012-6667</issn><issn>1179-1950</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkV1LIzEUhoO4aHX3L0hAvJxuzkw-Zi5rcVehsnvRXg-Z5ERHppOStEL_vRmmVQTB5CLnwPMeDk8IocCmOUjxG0BUAoBl7HjG6oRMAFSVQSXYKZkwBnkmpVTn5CLGl6GtRHVGznOoSgGST8jjUredD23_RJfPGPRmT50PdOGN7ro9ndlX3Ru09Dagjls6H7pAV3EIPPoOza7Tgf4P3rUdxp_kh9NdxF-H95Ks_twt5_fZ4t_fh_lskRnO5DZzvDGNtYyDBqPKQjpW5kJZpSzo3DasyA1K1ygstUiroqjAgXRoAFlRyuKSXI9zn3SHdds7vw3arNto6lmuWKEE5zxR0y-odC2uW-N7HHb-HCjHgAk-xoCu3oR2rcO-BlYP4uuj-Ppd_Fil6NUY3eyaNdr34NF0Am4OgI7JrQvJZBs_OK6YynmZuGrk4mb4FQz1i9-FPtn8fok3KWqZnQ</recordid><startdate>20110101</startdate><enddate>20110101</enddate><creator>Fosker, Christopher</creator><creator>Adlard, Julian W.</creator><creator>Shaaban, Abeer</creator><general>Springer International Publishing</general><general>Adis International</general><general>Wolters Kluwer Health, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20110101</creationdate><title>Tailoring Therapy for Locally Advanced Breast Cancer Using Molecular Profiles</title><author>Fosker, Christopher ; Adlard, Julian W. ; Shaaban, Abeer</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-f4bcbdd041a1c7836f08257d77d1a2db032ce6fb7e8a5198e591f16fec1e03863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - metabolism</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Current Opinion</topic><topic>Diagnosis</topic><topic>Estrogen Receptor Modulators - therapeutic use</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Pharmacology. Drug treatments</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacotherapy</topic><topic>Predictive Value of Tests</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fosker, Christopher</creatorcontrib><creatorcontrib>Adlard, Julian W.</creatorcontrib><creatorcontrib>Shaaban, Abeer</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Drugs (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fosker, Christopher</au><au>Adlard, Julian W.</au><au>Shaaban, Abeer</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tailoring Therapy for Locally Advanced Breast Cancer Using Molecular Profiles: Are We There Yet?</atitle><jtitle>Drugs (New York, N.Y.)</jtitle><stitle>Drugs</stitle><addtitle>Drugs</addtitle><date>2011-01-01</date><risdate>2011</risdate><volume>71</volume><issue>15</issue><spage>1947</spage><epage>1955</epage><pages>1947-1955</pages><issn>0012-6667</issn><eissn>1179-1950</eissn><coden>DRUGAY</coden><abstract>The term ‘locally advanced breast cancer’ covers a range of clinical scenarios, and has the implications that surgical clearance and local control will be difficult or impossible, and long-term survival rates will be poor. Treatment selection is particularly important in this group of patients to try to obtain maximum control of disease, and potentially improve surgical options and cure rates.
Currently, assessment of estrogen receptor, progesterone receptor and human epidermal receptor 2 status in tumour samples remains the gold standard for prediction of response to endocrine therapy, chemotherapy or targeted agents such as trastuzumab. Progress has been made in identifying markers that can help select treatments likely to be associated with response and avoid those associated with resistance. These potential markers include Ki67 proliferation rate, cytochrome P450 (CYP) 2D6 expression, BRCA1/2 gene status and others.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>21985164</pmid><doi>10.2165/11595110-000000000-00000</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-6667 |
| ispartof | Drugs (New York, N.Y.), 2011-01, Vol.71 (15), p.1947-1955 |
| issn | 0012-6667 1179-1950 |
| language | eng |
| recordid | cdi_gale_infotracmisc_A270375444 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Antineoplastic agents Antineoplastic Agents, Hormonal - therapeutic use Biological and medical sciences Biomarkers, Tumor - metabolism Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Cancer Care and treatment Chemotherapy Chemotherapy, Adjuvant Current Opinion Diagnosis Estrogen Receptor Modulators - therapeutic use Female Gynecology. Andrology. Obstetrics Health aspects Humans Internal Medicine Mammary gland diseases Medical sciences Medicine Medicine & Public Health Pharmacology. Drug treatments Pharmacology/Toxicology Pharmacotherapy Predictive Value of Tests Randomized Controlled Trials as Topic Receptor, ErbB-2 - metabolism Receptors, Progesterone - metabolism Severity of Illness Index Treatment Outcome Tumors |
| title | Tailoring Therapy for Locally Advanced Breast Cancer Using Molecular Profiles: Are We There Yet? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T20%3A34%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tailoring%20Therapy%20for%20Locally%20Advanced%20Breast%20Cancer%20Using%20Molecular%20Profiles:%20Are%20We%20There%20Yet?&rft.jtitle=Drugs%20(New%20York,%20N.Y.)&rft.au=Fosker,%20Christopher&rft.date=2011-01-01&rft.volume=71&rft.issue=15&rft.spage=1947&rft.epage=1955&rft.pages=1947-1955&rft.issn=0012-6667&rft.eissn=1179-1950&rft.coden=DRUGAY&rft_id=info:doi/10.2165/11595110-000000000-00000&rft_dat=%3Cgale_cross%3EA270375444%3C/gale_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/21985164&rft_galeid=A270375444&rfr_iscdi=true |